Takeaway

• Adding abiraterone (abi) to androgen deprivation therapy (ADT) + docetaxel resulted in an approximate benefit of 2.5 years median progression free survival in men with de novo metastatic prostate cancer.
• According to the presenter, the question is: “Should we deny patients approximately 2.5 years of absolute benefit in median...